InsiderSignalSign in

← Insider buys

RNA

Atrium Therapeutics, Inc. · Healthcare

Insiders sold $4.0M of Atrium Therapeutics, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$4.0MSold, 12 mo

$140.3MMarket cap

RNA over the last year

Prices for RNA aren't in yet.

RNA after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

63 insider filings since 2021, newest first

Michael F Maclean · CFO

$329K−7.0%Jan 23

Steven George Hughes · Chief Medical Officer

$355K−13.0%Jan 23

Sarah Boyce · President and CEO

$1.0M−5.0%Jan 23

W. Michael Flanagan · Chief Scientific Officer

$473K−7.0%Jan 23

Arthur A Levin · Director

$127K−1.0%Jan 23

Teresa Mccarthy · CHRO

$212K−3.0%Jan 23

Michael F Maclean · CFO

$143K−3.0%Jan 9

Sarah Boyce · President and CEO

$619K−3.0%Jan 9

Teresa Mccarthy · CHRO

$142K−2.0%Jan 9

John B Moriarty · General Counsel

$171K−3.0%Jan 9

Steven George Hughes · Chief Medical Officer

$171K−6.0%Jan 9

W. Michael Flanagan · Chief Scientific Officer

$171K−3.0%Jan 9

Teresa Mccarthy · CHRO

$1.0M−21.0%Nov 20

Arthur A Levin · Director

$140K−2.0%Nov 20

Michael F Maclean · CFO

$4.8M−53.0%Nov 8

Arthur A Levin · Director

$233K−3.0%Oct 23

Teresa Mccarthy · CHRO

$1.2M−21.0%Oct 17

Tamar Thompson · Director

$1.3M−100.0%Oct 9

W. Michael Flanagan · CSTO

$3.0M−42.0%Oct 3

Michael F Maclean · CFO

$506K−9.0%Sep 23

Teresa Mccarthy · CHRO

$579K−12.0%Sep 23

W. Michael Flanagan · CSTO

$1.1M−23.0%Sep 23

Sarah Boyce · President and CEO

$1.4M−10.0%Sep 23

Arthur A Levin · Director

$229K−3.0%Sep 20

W. Michael Flanagan · CSTO

$4.5M−65.0%Sep 13

Teresa Mccarthy · CHRO

$1.0M−30.0%Sep 13

Arthur A Levin · Director

$226K−3.0%Aug 21

Sarah Boyce · President and CEO

$1.2M−12.0%Aug 7

Arthur A Levin · Director

$225K−3.0%Jul 23

Sarah Boyce · President and CEO

$1.1M−12.0%Jul 11

Arthur A Levin · Director

$188K−3.0%Jun 21

Michael F Maclean · CFO

$439K−12.0%Jun 20

Teresa Mccarthy · CHRO

$386K−15.0%Jun 20

Sarah Boyce · President and CEO

$1.3M−14.0%Jun 20

W. Michael Flanagan · CSTO

$395K−12.0%Jun 20

Michael F Maclean · CFO

$3.7M−70.0%Jun 14

Arthur A Levin · Director

$3.8M−37.0%Jun 14

Sarah Boyce · President and CEO

$11.6M−73.0%Jun 14

Sarah Boyce · President and CEO

$768K−20.0%Jun 5

Arthur A Levin · Director

$149K−2.0%May 21

Michael F Maclean · CFO

$2.1M−63.0%May 16

Sarah Boyce · President and CEO

$715K−20.0%May 7

Arthur A Levin · Director

$114K−2.0%Apr 22

Arthur A Levin · Director

$542K−7.0%Apr 3

Sarah Boyce · President and CEO

$735K−20.0%Apr 3

Arthur A Levin · Director

$120K−2.0%Mar 21

Michael F Maclean · CFO

$981K−48.0%Mar 15

Arthur A Levin · Director

$609K−9.0%Mar 12

Sarah Boyce · President and CEO

$2.4M−50.0%Mar 12

Sarah Boyce · President and CEO

$1.7M−43.0%Mar 5

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.